CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 100.0%

Compliant submissions 1

Incompliant submissions 0

Total trials 1

My Organizations' Clinical Trials

Showing 1200 of 2228 entries

View as:

Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances

Phase: N/A Priority: Normal

NCT ID: NCT00356096 Org: User:

Start: 07/31/06 End: - Due: -

Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02183376 Org: User:

Start: 07/31/08 End: - Due: -

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT01958060 Org: User:

Start: 10/31/13 End: 04/30/14 Due: 04/30/15

To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days

Phase: N/A Priority: Normal

NCT ID: NCT02733627 Org: User:

Start: 07/07/16 End: 07/12/17 Due: 07/12/18

Greek NIS Spiolto ELLACTO

Phase: N/A Priority: Normal

NCT ID: NCT03419962 Org: User:

Start: 03/19/18 End: 04/03/19 Due: 04/03/20

Pharmacokinetics of Bisacodyl or Sodium Picosulfate Administered Orally in Healthy Lactating Females

Phase: N/A Priority: Normal

NCT ID: NCT02211911 Org: User:

Start: 02/29/08 End: - Due: -

Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT02262559 Org: User:

Start: 07/31/02 End: - Due: -

A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

Phase: N/A Priority: Normal

NCT ID: NCT05103657 Org: User:

Start: 12/07/21 End: 11/20/23 Due: 11/20/24

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

Phase: N/A Priority: Normal

NCT ID: NCT03859973 Org: User:

Start: 04/15/19 End: 11/04/22 Due: 11/04/23

Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain

Phase: N/A Priority: Normal

NCT ID: NCT02084511 Org: User:

Start: 03/31/14 End: 10/31/14 Due: 10/31/15

Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02171000 Org: User:

Start: 04/30/05 End: - Due: -

Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT02222168 Org: User:

Start: 09/04/14 End: 10/31/14 Due: 10/31/15

Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT02182336 Org: User:

Start: 06/30/08 End: - Due: -

PraxbindTM India PMS Program

Phase: N/A Priority: Normal

NCT ID: NCT03359889 Org: User:

Start: 12/26/18 End: 01/13/20 Due: 01/13/21

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated

Phase: N/A Priority: Normal

NCT ID: NCT05183347 Org: User:

Start: 02/04/22 End: 07/27/22 Due: 07/27/23

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

Phase: N/A Priority: Normal

NCT ID: NCT04822701 Org: User:

Start: 04/21/21 End: 10/04/21 Due: 10/04/22

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Phase: N/A Priority: Normal

NCT ID: NCT00905632 Org: User:

Start: 05/31/09 End: - Due: -

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT02262624 Org: User:

Start: 02/28/05 End: - Due: -

Klimadynon® in Comparison to Conjugated Oestrogens in Women Suffering From Menopausal Complaints

Phase: N/A Priority: Normal

NCT ID: NCT02184364 Org: User:

Start: 11/30/98 End: - Due: -

Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal

NCT ID: NCT01947855 Org: User:

Start: 09/30/13 End: 12/31/13 Due: 12/31/14

Afatinib in NSCLC With HER2 Mutation

Phase: N/A Priority: Normal

NCT ID: NCT02597946 Org: User:

Start: 03/18/16 End: 07/22/18 Due: 07/22/19

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Phase: N/A Priority: Normal

NCT ID: NCT04521478 Org: User:

Start: 11/20/20 End: 02/02/24 Due: 02/02/25

A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions

Phase: N/A Priority: Normal

NCT ID: NCT03854578 Org: User:

Start: 03/12/19 End: 09/23/19 Due: 09/23/20

Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD

Phase: N/A Priority: Normal

NCT ID: NCT02683109 Org: User:

Start: 03/08/16 End: 01/30/17 Due: 01/30/18

Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT02226991 Org: User:

Start: 04/30/06 End: - Due: -

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances	NCT00356096	Boehringer Ingelheim	user2@example.com	None	2006-07-31	-	-	-	-	2025-07-14
Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects	NCT02183376	Boehringer Ingelheim	user2@example.com	None	2008-07-31	-	-	-	-	2025-07-14
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers	NCT01958060	Boehringer Ingelheim	user2@example.com	None	2013-10-31	2014-04-30	2015-04-30	-	-	2025-07-14
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days	NCT02733627	Boehringer Ingelheim	user2@example.com	None	2016-07-07	2017-07-12	2018-07-12	-	-	2025-07-14
Greek NIS Spiolto ELLACTO	NCT03419962	Boehringer Ingelheim	user2@example.com	None	2018-03-19	2019-04-03	2020-04-03	-	-	2025-07-14
Pharmacokinetics of Bisacodyl or Sodium Picosulfate Administered Orally in Healthy Lactating Females	NCT02211911	Boehringer Ingelheim	user2@example.com	None	2008-02-29	-	-	-	-	2025-07-14
Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers	NCT02262559	Boehringer Ingelheim	user2@example.com	None	2002-07-31	-	-	-	-	2025-07-14
A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder	NCT05103657	Boehringer Ingelheim	user2@example.com	None	2021-12-07	2023-11-20	2024-11-20	-	-	2025-07-14
This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia	NCT03859973	Boehringer Ingelheim	user2@example.com	None	2019-04-15	2022-11-04	2023-11-04	-	-	2025-07-14
Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain	NCT02084511	Boehringer Ingelheim	user2@example.com	None	2014-03-31	2014-10-31	2015-10-31	-	-	2025-07-14
Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects	NCT02171000	Boehringer Ingelheim	user2@example.com	None	2005-04-30	-	-	-	-	2025-07-14
Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers	NCT02222168	Boehringer Ingelheim	user2@example.com	None	2014-09-04	2014-10-31	2015-10-31	-	-	2025-07-14
Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers	NCT02182336	Boehringer Ingelheim	user2@example.com	None	2008-06-30	-	-	-	-	2025-07-14
PraxbindTM India PMS Program	NCT03359889	Boehringer Ingelheim	user2@example.com	None	2018-12-26	2020-01-13	2021-01-13	-	-	2025-07-14
A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated	NCT05183347	Boehringer Ingelheim	user2@example.com	None	2022-02-04	2022-07-27	2023-07-27	-	-	2025-07-14
A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19	NCT04822701	Boehringer Ingelheim	user2@example.com	None	2021-04-21	2021-10-04	2022-10-04	-	-	2025-07-14
4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients	NCT00905632	Boehringer Ingelheim	user2@example.com	None	2009-05-31	-	-	-	-	2025-07-14
Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers	NCT02262624	Boehringer Ingelheim	user2@example.com	None	2005-02-28	-	-	-	-	2025-07-14
Klimadynon® in Comparison to Conjugated Oestrogens in Women Suffering From Menopausal Complaints	NCT02184364	Boehringer Ingelheim	user2@example.com	None	1998-11-30	-	-	-	-	2025-07-14
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus	NCT01947855	Boehringer Ingelheim	user2@example.com	None	2013-09-30	2013-12-31	2014-12-31	-	-	2025-07-14
Afatinib in NSCLC With HER2 Mutation	NCT02597946	Boehringer Ingelheim	user2@example.com	None	2016-03-18	2018-07-22	2019-07-22	-	-	2025-07-14
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression	NCT04521478	Boehringer Ingelheim	user2@example.com	None	2020-11-20	2024-02-02	2025-02-02	-	-	2025-07-14
A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions	NCT03854578	Boehringer Ingelheim	user2@example.com	None	2019-03-12	2019-09-23	2020-09-23	-	-	2025-07-14
Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD	NCT02683109	Boehringer Ingelheim	user2@example.com	None	2016-03-08	2017-01-30	2018-01-30	-	-	2025-07-14
Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers	NCT02226991	Boehringer Ingelheim	user2@example.com	None	2006-04-30	-	-	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance